- Home
- ADV vs ZVRA Comparison
ADV vs ZVRA Comparison
Compare ADV & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- ZVRA
- Stock Information
- Founded
- ADV 1987
- ZVRA 2006
- Country
- ADV United States
- ZVRA United States
- Employees
- ADV N/A
- ZVRA N/A
- Industry
- ADV Business Services
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- ZVRA Health Care
- Exchange
- ADV Nasdaq
- ZVRA Nasdaq
- Market Cap
- ADV 495.4M
- ZVRA 467.6M
- IPO Year
- ADV N/A
- ZVRA 2015
- Fundamental
- Price
- ADV $1.49
- ZVRA $10.62
- Analyst Decision
- ADV Strong Buy
- ZVRA Strong Buy
- Analyst Count
- ADV 1
- ZVRA 7
- Target Price
- ADV $2.50
- ZVRA $22.57
- AVG Volume (30 Days)
- ADV 411.6K
- ZVRA 1.9M
- Earning Date
- ADV 11-06-2025
- ZVRA 11-11-2025
- Dividend Yield
- ADV N/A
- ZVRA N/A
- EPS Growth
- ADV N/A
- ZVRA N/A
- EPS
- ADV N/A
- ZVRA N/A
- Revenue
- ADV $3,527,054,000.00
- ZVRA $62,020,000.00
- Revenue This Year
- ADV N/A
- ZVRA $336.43
- Revenue Next Year
- ADV $0.67
- ZVRA $54.26
- P/E Ratio
- ADV N/A
- ZVRA N/A
- Revenue Growth
- ADV N/A
- ZVRA 161.81
- 52 Week Low
- ADV $1.04
- ZVRA $6.19
- 52 Week High
- ADV $4.04
- ZVRA $13.16
- Technical
- Relative Strength Index (RSI)
- ADV 45.84
- ZVRA 53.76
- Support Level
- ADV $1.40
- ZVRA $10.46
- Resistance Level
- ADV $1.49
- ZVRA $11.24
- Average True Range (ATR)
- ADV 0.09
- ZVRA 0.62
- MACD
- ADV 0.01
- ZVRA -0.03
- Stochastic Oscillator
- ADV 60.87
- ZVRA 32.86
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.